BPA
RLMD icon

Beacon Pointe Advisors’s Relmada Therapeutics RLMD Stock Holding History

Beacon Pointe Advisors’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,090
Closed -$32.7K – 1270
2024
Q3 		$32.7K Hold
10,090
– – ﹤0.01% 1207
2024
Q2 		$30.3K Buy
+10,090
New +$36.5K ﹤0.01% 1250

Other funds holding RLMD

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Beacon Pointe Advisors's RLMD Position: Q4 2024 in Review

Beacon Pointe Advisors sold out of Relmada Therapeutics (RLMD) in Q4 2024, closing a stake of 10,090 shares — an estimated $32.7K sold.

Beacon Pointe Advisors first reported a position in RLMD in Q2 2024 and held it in 2 quarters. The position peaked at $32.7K in Q3 2024. 48 funds tracked by Wall St. Rank hold RLMD as of Q4 2024.

  • Beacon Pointe Advisors reported no remaining Relmada Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Beacon Pointe Advisors sold 10,090 Relmada Therapeutics shares in Q4 2024, an estimated $32.7K.
  • Beacon Pointe Advisors first reported a position in Relmada Therapeutics in Q2 2024 and held it in 2 quarters.
  • Beacon Pointe Advisors's Relmada Therapeutics position peaked at $32.7K in Q3 2024.
  • 48 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2024.

Based on Beacon Pointe Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.